Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.

van der Ree, M H; van der Meer, A J; van Nuenen, A C; de Bruijne, J; Ottosen, S; Janssen, H L; Kootstra, N A; Reesink, H W

van der Ree, M H; van der Meer, A J; van Nuenen, A C; de Bruijne, J; Ottosen, S; Janssen, H L; Kootstra, N A; Reesink, H W.

Affiliation

van der Ree MH; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.
van der Meer AJ; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
van Nuenen AC; Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.
de Bruijne J; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
Ottosen S; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.
Janssen HL; Santaris Pharma A/S, Hørsholm, Denmark.
Kootstra NA; Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands.
Reesink HW; Liver Clinic, Toronto Western & General Hospital, University Health Network, Toronto, ON, Canada.

Aliment Pharmacol Ther ; 43(1): 102-13, 2016 Jan.

Article in En | MEDLINE | ID: mdl-26503793

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oligonucleotides / Hepatitis C, Chronic / MicroRNAs Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2016 Document type: Article Affiliation country: Países Bajos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google